Who is sponsoring NCT07508592?

NCT07508592 is sponsored by Seger Surgical Solutions.

What drugs are being tested in NCT07508592?

Interventions in NCT07508592: SEGER Device.

What condition does NCT07508592 study?

NCT07508592 studies Gastrointestinal Surgical Procedures, Anastomosis, Surgical, Enterotomy, Laparoscopy-assisted Surgery.

Is NCT07508592 still recruiting?

NCT07508592 is currently recruiting now. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT07508592: SEGER-FIH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery

Recruiting now NA Last updated 2 April 2026

What this trial tests

NA trial testing SEGER Device in Gastrointestinal Surgical Procedures in 10 participants. Currently enrolling.

Timeline

17 February 2026

Primary endpoint
1 August 2026

1 September 2026

Quick facts

Lead sponsor	Seger Surgical Solutions
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	10
Start date	17 February 2026
Primary completion	1 August 2026
Estimated completion	1 September 2026
Sites	1 location across El Salvador

Drugs / interventions tested

SEGER Device

Conditions studied

Gastrointestinal Surgical Procedures — all drugs for Gastrointestinal Surgical Procedures →
Anastomosis, Surgical — all drugs for Anastomosis, Surgical →
Enterotomy — all drugs for Enterotomy →
Laparoscopy-assisted Surgery — all drugs for Laparoscopy-assisted Surgery →

Sponsor

Seger Surgical Solutions

Who can join

Adults 18 to 80, any sex, with Gastrointestinal Surgical Procedures or Anastomosis, Surgical. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis. The study will include patients undergoing procedures such as small bowel-small bowel and colorectal anastomoses. The SEGER device is intended to facilitate closure of enterotomies and support intracorporeal anastomosis during minimally invasive surgery. The primary objective of the study is to assess the safety of the device and its performance during surgery. Secondary objectives include evaluation of technical success, intraoperative usability, and early postoperative outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07508592 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seger Surgical Solutions
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07508592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing